Loading patent…
AssigneeIBC Pharmaceuticals, Inc.
InventorsChien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi, Hans J. Hansen
Estimating the term…
The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-α, interferon-β, interferon-λ1, interferon-λ2 or interferon-λ3.
A method of directing effector T cells to a cancer cell that expresses human Trop-2 or CEACAM5 in an individual comprising administering to the individual a T-cell redirecting complex comprising a bispecific antibody, wherein the bispecific antibody consists of (i) two copies of a first antibody or antigen-binding fragment thereof selected from the group consisting of hRS7 and hMN-14, and (ii) one copy of a second antibody or antigen-binding fragment thereof that is Okt3.
A method of treating a cancer that expresses human Trop-2 or CEACAM5 comprising administering to an individual with a cancer that expresses human Trop-2 or CEACAM5 a T-cell redirecting complex comprising a bispecific antibody, wherein the bispecific antibody consists of (i) two copies of a first antibody or antigen-binding fragment thereof selected from the group consisting of hRS7 and hMN-14, and (ii) one copy of a second antibody or antigen-binding fragment thereof that is Okt3.
Dependencies are inferred from the claim text.